Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl-Reference-Cited by-同舟云学术

Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl

Published:2017-11 Issue:11 Volume:39 Page:2158-2168
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Anthony Lowell,Ervin Claire,Lapuerta Pablo,Kulke Matthew H.,Kunz Pamela,Bergsland Emily,Hörsch Dieter,Metz David C.,Pasieka Janice,Pavlakis Nick,Pavel Marianne,Caplin Martyn,Öberg Kjell,Ramage John,Evans Emily,Yang Qi Melissa,Jackson Shanna,Arnold Karie,Law Linda,DiBenedetti Dana B.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference23 articles.

1. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors;Turaga;CA Cancer J Clin,2011

2. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States;Yao;J Clin Oncol,2008

3. Carcinoid tumors;Kulke;N Engl J Med,1999

4. Carcinoid tumors and the carcinoid syndrome. In: Neuroendocrine tumors; a comprehensive guide to diagnosis and management;Vinik,2006

5. SEER Stat Database: SEER 17 Regs Nov 2006 sub (1973–2004),2007

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrating qualitative interviews in drug development and the use of qualitative evidence in product labelling and health technology assessments: a review;Frontiers in Medicine;2023-06-20

2. Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors;Expert Review of Anticancer Therapy;2023-05-15

3. Real-World Clinical and Patient-Reported Outcomes from the Longitudinal Telotristat Ethyl Treatment Registry of Patients with Neuroendocrine Tumors;Cancer Management and Research;2022-10

4. Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes;The Patient - Patient-Centered Outcomes Research;2022-05

5. Changes in Carcinoid Syndrome Symptoms Among Patients Receiving Telotristat Ethyl in US Clinical Practice: Findings from the TELEPRO-II Real-World Study;Cancer Management and Research;2021-09